里昂:继续看好石药集团的发展 维持“高度确信跑赢大市”评级

GoldenOctober2024
SYS-2,04%

金十数据5月30日讯,里昂发表研究报告指,虽然石药集团(01093.HK)的恩必普及多美素销售面临挑战,但首季业绩表现仍符合预期,净利润按年下跌8.4%,相信石药的盈利已于首季触底。除市场关注的SYS6010外,管理层亦透露有另外两项产品将达成潜在授权合作,规模均超过50亿美元。里昂表示继续看好石药的发展,认为其早期研发管线在全球具备竞争力,并拥有差异化创新药平台,维持石药的“高度确信跑赢大市”评级,目标价为13.8港元。

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Commento
0/400
Nessun commento
Trading di criptovalute ovunque e in qualsiasi momento
qrCode
Scansiona per scaricare Gate app
Notizie
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)